New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 29, 2014
09:25 EDTMYL, MYL, ATI, ATI, IIVI, IIVI, KOP, KOP, ANSS, ANSS, FSTR, FSTR, BBOX, BBOX, KMT, KMT, STBA, STBA, CCC, CCC, EQT, EQT, WCC, WCCCFA Society of Pittsburgh to hold a conference
2014 INVESTPennsylvania Equity Conference to be held in Pittsburgh on May 29 with webcasted company presentations to begin at 9:25 am; not all company presentations may be webcasted. Webcast Link
News For MYL;EQT;CCC;STBA;KMT;BBOX;FSTR;ANSS;KOP;IIVI;ATI;WCC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
December 16, 2014
09:52 EDTMYLFDA ruling on generic Celebrex reversed by appeals court
Subscribe for More Information
08:47 EDTATIAllegheny Technologies upgraded at Sterne Agee
Subscribe for More Information
07:39 EDTATIAllegheny Technologies upgraded to Buy from Neutral at Sterne Agee
Subscribe for More Information
December 12, 2014
09:32 EDTKMTKennametal shares may respond negatively to weaker trends, says Wells Fargo
Subscribe for More Information
09:19 EDTKMTKennametal reports consolidated orders up 4% in three months end November
Subscribe for More Information
December 11, 2014
09:04 EDTWCCWESCO to host conference call
Subscribe for More Information
07:32 EDTMYLMylan launches generic version of Hikma Maple's Robaxin injection
Subscribe for More Information
07:30 EDTIIVIDA Davidson to hold a conference
6th Annual Aerospace & Industrials 1:1 Conference is being held in Boston on December 11.
07:06 EDTMYLMylan launches generic version of Orapred ODT
Mylan announced the U.S. launch of its Prednisolone Sodium Phosphate Orally Disintegrating Tablets, 10 mg, 15 mg, and 30 mg. This product is the first generic version of Shionogi's Orapred ODT. Mylan received final approval from the FDA for its Abbreviated New Drug Application for Prednisolone Sodium Phosphate Orally Disintegrating Tablets, 10 mg, 15 mg, and 30 mg, and was awarded 180 days of generic drug marketing exclusivity. This product is indicated as an anti-inflammatory or immunosuppressive agent for certain conditions; and also for the treatment of certain endocrine conditions, and for palliation of certain neoplastic conditions. Prednisolone Sodium Phosphate Orally Disintegrating Tablets had U.S. sales of approximately $19.9M for the 12 months ending September 30.
December 10, 2014
10:00 EDTEQTOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:38 EDTMYLMylan launches generic version of Pfizer's Celebrex capsules
Mylan (MYL) announced the U.S. launch of its Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg, one of the first available generic versions of Pfizer's (PFE) Celebrex Capsules, indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults. Celecoxib Capsules had U.S. sales of approximately $2.5B for the 12 months ending September 30, 2014.
07:22 EDTEQTEQT Corporation upgraded to Buy from Accumulate at KLR Group
Subscribe for More Information
December 8, 2014
11:30 EDTMYLLeerink generics pharmaceutical analyst holds analyst/industry conference call
Subscribe for More Information
09:03 EDTWCCConcurrent announces strategic agreement with WESCO division
Concurrent (CCUR) announced a strategic agreement with TVC Communications, a division of WESCO Distribution (WCC), to resell Concurrent’s UpShift Unified Content Delivery Solution to customers throughout the Caribbean and Latin America.
07:31 EDTEQTEQT Corporation plans registration statement for EQT Midstream Partners
Subscribe for More Information
07:08 EDTEQTEQT Midstream Partners sees 2015 adjusted EBITDA $330M-$345M
Subscribe for More Information
07:06 EDTEQTEQT Corporation sees 2015 sales volume 575 – 600 Bcfe
Subscribe for More Information
07:04 EDTEQTEQT Corporation sees 2015 capital expenditures $2.5B
EQT Corporation (EQT) announced the company’s 2015 capital expenditure forecast of $2.5B, excluding business development and land acquisitions. The CAPEX forecast includes $2.3B for EQT Production and $225M-$250M for EQT Midstream depending on the timing of an expected drop-down. Funding will be provided by cash generated from operations, cash-on-hand, and proceeds from midstream asset sales to EQT Midstream Partners, LP (EQM). EQT’s 2015 CAPEX forecast excludes CAPEX for EQT Midstream Partners, LP, a master limited partnership controlled by EQT Corporation and consolidated in EQT’s financial statements.
December 5, 2014
10:05 EDTMYLBristol-Myers jumps 2% amid talk of potential Pfizer bid
Shares of Bristol-Myers (BMY) are up in early trading amid chatter of a potential takeover bid from Pfizer (PFE). The stock is up $1.26 to $60.15. Bristol's market capitalization stands around $99B, less than twice that of Pfizer's $200B. A Jefferies analyst last week called Mylan (MYL) the most likely takeover target for Pfizer. Pfizer is "highly motivated" to buy a foreign company using its overseas cash and Mylan looks like the most likely target, Jefferies analyst Jeffrey Holford wrote.
December 4, 2014
10:03 EDTMYLMylan receives tentative FDA approval for abacavir/lamivudine NDAs
Mylan announced that its subsidiary Mylan Laboratories has received tentative approval from the FDA for its New Drug Applications for two dosages of abacavir/lamivudine tablets for oral suspension for the treatment of HIV-1 infection in pediatric patients. This is the first version of abacavir/lamivudine with scoring to allow for dose adjustment and is also flavored, Mylan said. The FDA's tentative approval through the President's Emergency Plan for AIDS Relief program means the formulations meet all of the agency's quality, safety and efficacy standards, it stated. The tentative approval follows a 2012 agreement between Mylan, Clinton Health Access Initiative and ViiV Healthcare to transfer the necessary technology and resources to facilitate regulatory authority submission, production and distribution of the new formulation to a total of 115 resource limited countries including all low-middle income, least developed countries and sub-Saharan Africa. Mylan's products are expected to be eligible for purchase in early 2015.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use